These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 19100416)

  • 1. Therapeutic effect of Tripterygium wilfordii on proteinuria associated with sirolimus in renal transplant recipients.
    Ji SM; Li LS; Wen JQ; Sha GZ; Cheng Z; Cheng DR; Chen JS; Liu ZH
    Transplant Proc; 2008 Dec; 40(10):3474-8. PubMed ID: 19100416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical trial of Tripterygium Wilfordii Hook F. in human kidney transplantation in China.
    Ji SM; Wang QW; Chen JS; Sha GZ; Liu ZH; Li LS
    Transplant Proc; 2006 Jun; 38(5):1274-9. PubMed ID: 16797280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteinuria after conversion to sirolimus in renal transplant recipients.
    Sahin GM; Sahin S; Kantarci G; Ergin H
    Transplant Proc; 2006 Dec; 38(10):3473-5. PubMed ID: 17175308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteinuria in transplant patients associated with sirolimus.
    Franco AF; Martini D; Abensur H; Noronha IL
    Transplant Proc; 2007 Mar; 39(2):449-52. PubMed ID: 17362756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of sirolimus on proteinuria in de novo kidney transplantation with expanded criteria donors: comparison of two CNI-free protocols.
    Diekmann F; Gutiérrez-Dalmau A; López S; Cofán F; Esforzado N; Ricart MJ; Rossich E; Saval N; Torregrosa JV; Oppenheimer F; Campistol JM
    Nephrol Dial Transplant; 2007 Aug; 22(8):2316-21. PubMed ID: 17452413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of diabetic nephropathy with Tripterygium wilfordii Hook F extract: a prospective, randomized, controlled clinical trial.
    Ge Y; Xie H; Li S; Jin B; Hou J; Zhang H; Shi M; Liu Z
    J Transl Med; 2013 May; 11():134. PubMed ID: 23725518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors associated with proteinuria in renal transplant recipients treated with sirolimus.
    Liew A; Chiang GS; Vathsala A
    Transpl Int; 2009 Mar; 22(3):313-22. PubMed ID: 19054382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conversion from a calcineurin inhibitor-based immunosuppressive regimen to everolimus in renal transplant recipients: effect on renal function and proteinuria.
    Morales J; Fierro A; Benavente D; Zehnder C; Ferrario M; Contreras L; Herzog C; Buckel E
    Transplant Proc; 2007 Apr; 39(3):591-3. PubMed ID: 17445551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolution of glomerular filtration rate, renal injury markers, anemia, and angiotensin blockers use after change from calcineurin inhibitors to sirolimus in transplant patients with neoplasia versus chronic allograft nephropathy.
    Luna E; Cerezo I; Macias R; Villa J; Martinez C; Cubero J; Martinez R; Ferreira F; García C
    Transplant Proc; 2011; 43(6):2187-90. PubMed ID: 21839229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the efficacy and safety of TWHF in diabetic nephropathy patients with overt proteinuria and normal eGFR.
    Xiong C; Li L; Bo W; Chen H; XiaoWei L; Hongbao L; Peng Z
    J Formos Med Assoc; 2020 Mar; 119(3):685-692. PubMed ID: 31801679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Valsartan-induced hematocrit changes in renal transplant patients.
    Flores CA; Ardiles LG; Aros CA; Muñoz CC; Schneider HO; Ramírez JA; Jerez V; Valderrama MG; Mezzano SA
    Transplant Proc; 2005 Apr; 37(3):1586-8. PubMed ID: 15866681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is sirolimus responsible for proteinuria?
    Dervaux T; Caillard S; Meyer C; Ellero B; Woehl-Jaegle ML; Hannedouche T; Wolf P; Moulin B
    Transplant Proc; 2005; 37(6):2828-9. PubMed ID: 16182822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
    Gaber AO; Kahan BD; Van Buren C; Schulman SL; Scarola J; Neylan JF;
    Transplantation; 2008 Nov; 86(9):1187-95. PubMed ID: 19005398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Therapeutic effect of Tripterygium wilfordii multiglycosides on proteinuria in kidney transplant recipients].
    Huang Y; Long TB; Zhan F; Pan CY; Chen DJ; Lin SD
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Dec; 28(12):2269-71. PubMed ID: 19114376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subclinical Lesions and Donor-Specific Antibodies in Kidney Transplant Recipients Receiving Tacrolimus-Based Immunosuppressive Regimen Followed by Early Conversion to Sirolimus.
    de Sandes-Freitas TV; Felipe CR; Campos ÉF; de Lima MG; Soares MF; de Franco MF; Aguiar WF; Tedesco-Silva H; Medina-Pestana JO
    Transplantation; 2015 Nov; 99(11):2372-81. PubMed ID: 25929604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conversion to sirolimus-based maintenance immunosuppression using daclizumab bridge therapy in renal transplant recipients.
    Sundberg AK; Rohr MS; Hartmann EL; Adams PL; Stratta RJ
    Clin Transplant; 2004; 18 Suppl 12():61-6. PubMed ID: 15217410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early sirolimus therapy in renal transplant recipients at high risk: is it justified?
    Halim MA; Al-Otaibi T; Johny KV; Hamid MH; Al-Waheeb S; Hasaneen H; Awadain WH; Nawas KM; El-Sayed A; Said T; Nair MP; Nampoory MR
    Transplant Proc; 2009 Sep; 41(7):2784-8. PubMed ID: 19765435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mycophenolate mofetil vs. sirolimus in kidney transplant recipients receiving tacrolimus-based immunosuppressive regimen.
    Sampaio EL; Pinheiro-Machado PG; Garcia R; Felipe CR; Park SI; Casarini DE; Moreira S; Franco MF; Tedesco-Silva H; Medina-Pestana JO
    Clin Transplant; 2008; 22(2):141-9. PubMed ID: 18339132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term follow-up of 100 high-risk renal transplant recipients converted from calcineurin inhibitors to sirolimus: a single center experience.
    Halim MA; Al-Otaibi T; Johny KV; Hamid MH; Tawab KA; Balaha MA; Abraham M; Said T; Nair MP; Al-Waheeb S; Al-Muzairai I; Nampoory MR
    Transplant Proc; 2009 Jun; 41(5):1666-70. PubMed ID: 19545704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.